Australian people can buy antibiotics in Australia online here: http://buyantibioticsaustralia.com/ No prescription required and cheap price!

Untitled

(combined response)
(lamivudine)
(adefovir dipivoxil)
(entecavir)
1 Strader DB, Wright T, Thomas DL, and Seeff LB. Diagnosis, management, and treatment of hepatitis C. 2 Seeger C, Mason W. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000, 64:51-68. 3 Scaglioni PP, Melegari M, Wands JR. Biologic properities of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology, 1997, 233:374-381. 4 Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis, 2003, 36:687-696. 5 Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat, 2002, 9: 243-257. 6 Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, 2005, 365:123-129. 7 World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 dex. (Revised October 2000). WHO Web site .http://www.who.int/mediacentre/ factsheets/fs204/en/ in html. 10 EASL International Consensus Conference on Hepatitis B. J Hepatol 2003, 39 (Suppl):S3-S25. 11 Lok ASF, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 summary of a workshop. 12 McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis, 1985, 151:599-603. 13 Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology, 1990, 99:805-810. 14 McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med, 2001,135:759-768. 15 Liaw YF, Tai DI, Chu CW, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology, 1988, 8:493-496. 16 Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg serocoversion in patients with chronic hepatitis B. Hepatology, 2002, 35:1522-1527. 17 Liaw YF, Tai DI, Chu CW, et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver, 1989, 9:235-241. 18 Di Marco V, Lo Lacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology, 19 Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology, 1989,10:198-202. 20 Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology, 1988, 8:1651-1654. 21 Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 2004, 351:1521-1531. 22 Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J 23 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 2004, 11:97-107. 24 Tai DI, Chen CH, Chang TT, et al. Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infection. J Gastroenterol Hepatol, 2002, 17:682-689. 27 Hepatitis B. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2002 2./ou/. 28 29 World Health Organization. Hepatitis B and breastfeeding. http://www.who.int /child-adolescent -health/New_Publications /NUTRITION/updt –22.htm (online on Oct 23, 2005) 30 John T J Cooksley G . Hepatitis B vaccine boosters: Is there a clinical need in high endemicity populations? J Gastroenterol Hepatol, 2005, 20:5-10. 31 Updated U.S. public health service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep, 2001, 50 (RR-11):1-52. 33 Roque-Afonse AM, Ferey MP, Mackiewicz V, et al. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients, performance of CLIP sequencing and line probe assay. Antivir Ther, 2003, 8:627-634. 34 Whalley SA, Brown D, Teo CG, et al. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using LightCycler. J Clin Microbiol, 2001, 39:1456-1459. 35 Ishak KG. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol, 2000, 36 Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1998, 11:431-435. 37 Scheuer PJ. Standish RA. Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis, 2002, 2002, 38 Chevallier M, Guerret S, Chossegros P, et al. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology, 1994, 20:349-355. 39 Wong DK,Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med, 1993, 119:312-323. 40 Lampertico P, Del Ninno E, Manzin A et al. A randomized, controlled trial of a 24-month course of interferon alpha 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis e antigen in serum. Hepatology, 1997, 26:1621-1625. 41 Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology, 1992, 15:584-589. 42 Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology, 2001, 121: 101-109. 45 Hoofnagle JH, DiBisceglie AM, Waggoner JG, et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology, 1993, 104:1116-1121. 46 Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin 47 Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352:2682-2695. 48 Marcellin P, Lau GKK, Bonino F, et al. Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351:1206- 1217. 49 Cooksley WGF, Piratvisuth T, Lee SD, et al. Peginterferon alpha 2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat, 2003, 10:298-305. 50 Carreno V, Marcellin P, Hadziyannis S, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis 51 Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis EUROHEP . Hepatology, 1999, 30:238-243. 52 Sokal R. Drug treatment of paediatric chronic hepatitis B. Peadiatr Drugs, 2002, 4: 361-369. 53 Hoofnagle JH, Dibisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med, 54 Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? Hepatology, 1989, 10:761-763. 55 Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003, 125:1714-1722. 56 Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 1998, 339:61-68. 57 Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 2000, 119:172-180. 58 Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 1999, 341:1256-1263. 59 Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology, 1999, 30:770-774. 60 Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. 61 Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000, 31:207-210. 62 Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology, 2001, 33:424-432. 63 Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl, 2003, 9:49-56. 64 Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. 65 Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al. Efficacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res, 2005, 31:217-222. 68 Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology, 1999, 30:567-572. 69 Liu CJ, Huang WL, Chen PJ, et al. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol, 2004, 10:3574-3578. 70 Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003, 348:808-816. 71 Macellin P, Chang TT, Lim S, et al. Long term efficacy and safety of adefovir dipivoxil 10 mg in HBeAg + chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time. Hepatology, 2004, 40 (4, suppl ):655A. 72 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 2003, 348:800-807. 73 Locarnini S, Shaw T, Sozzi T, et al. HBV mutants associated with clinical resistance to adefovir dipivoxil display only small decreases in antiviral sensitivity in vitro. Hepatology, 2004, 40 (4 suppl): 244A. 74 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 2005, 352:2673-2681. 75 Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 2004, 126:91-101. 76 Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology, 2004, 126:81-90. 77 Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int, 2004, 66:1153- 1158. 78 Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 2002, 123:1831-1838. 81 Colonno RJ, Rose R, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients. Hepatology, 2004, 40(4, suppl 1) :661A. 85 Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International, 2005, 25:472-489.

Source: http://weisheng.shmtu.edu.cn/hospital/attachments/129_%E6%85%A2%E6%80%A7%E4%B9%99%E8%82%9D%E9%98%B2%E6%B2%BB%E6%8C%87%E5%8D%97.pdf

Sd77-13_-_acs_shampoo_(de)

ABSCHNITT 1: Bezeichnung des Stoffs bzw. des Gemischs und des UnternehmensKeine weiteren relevanten Informationen verfügbar. · 1.3 Einzelheiten zum Lieferanten, der das Sicherheitsdatenblatt bereitstellt· Hersteller/Lieferant:AUWA-Chemie GmbHArgonstraße 786153 Augsburg / DEUTSCHLANDTelefon: +49-(0)821-55 84 2900Fax: +49-(0)821-55 84 2908Homepage: www.auwa.deTechnische Auskunft washtec@wash

Sentença

https://eproc4.jfpr.jus.br/eprocV2/controlador.php?acao=acessar_doc. AÇÃO CIVIL PÚBLICA Nº 5016365-58.2011.404.7001/PR : MINISTÉRIO PÚBLICO FEDERAL : ESTADO DO PARANÁ : UNIÃO - ADVOCACIA GERAL DA UNIÃO SENTENÇA O Ministério Público Federal ajuizou a presente ação civil pública objetivando condenação da União e do Estado do Paraná ao fornecimento do

Copyright © 2010-2014 Find Medical Article